Scancell research collaboration deal with European biopharma BioNTech

Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer. Scancell Co-Founder and Non-Executive Director Richard Goodfellow tells Proactive why the deal is significant for investors. The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors.